The role of ocrelizumab in recommendations and in the Polish therapeutic programme DOI Creative Commons
K Kubicka

Aktualności Neurologiczne, Год журнала: 2023, Номер 23(3), С. 111 - 117

Опубликована: Дек. 28, 2023

Multiple sclerosis is a heterogeneous and chronic disease, the primary goal of treatment to prevent relapses slow progression disability. Ocrelizumab generally well-tolerated disease-modifying therapy for multiple sclerosis, with high efficacy in active relapsing forms, valuable method delaying disease patients progressive form. The activity defined on basis clinical course or radiological findings assessed over year. occurrence and/or magnetic resonance imaging taken into account. In line recommendations European Committee Treatment Research Sclerosis Academy Neurology, as well accordance guidelines American updated 2021, depending early stage choice drug should be motivated by higher efficacy. Recommendations most countries Europe around world are based above-mentioned guidelines. Poland, modifying were developed 2023 experts from Neuroimmunology Section Polish Neurological Society. B.29 programme National Health Fund Poland allows, 1 July 2023, addition escalation, using induction model highly effective therapies first-line treatment.

Язык: Английский

The use of modafinil for the treatment of fatigue in multiple sclerosis: A systematic review and meta‐analysis of controlled clinical trials DOI Creative Commons
Shamas Ghazanfar, Minaam Farooq, Shurjeel Uddin Qazi

и другие.

Brain and Behavior, Год журнала: 2024, Номер 14(7)

Опубликована: Июль 1, 2024

Abstract Introduction Multiple sclerosis (MS) is a debilitating neurological condition affecting nearly one million people across the United States. Among most prominent symptoms of are excessive fatigue and daytime sleepiness. Numerous clinical trials have investigated efficacy modafinil in addressing among these patients. Objective The objective present study to assess safety for treatment MS. Methodology An electronic search PUBMED, ScienceDirect, Cochrane Central was conducted articles published from inception December 2023 using terms such as “modafinil,” “fatigue,” “MS.” Results Seven studies were included our analysis. Modafinil leads meaningful reduction when compared with placebo, measured by Modified Fatigue Impact Scale [mean difference (MD) = −4.42 [−8.01, −.84]; I 2 45%; p .02] Epworth Sleepiness [MD −.87 [−1.64, −.10]; 0%; .03]. also demonstrated greater risk precipitating adverse events (e.g., insomnia, gastrointestinal symptoms) placebo [RR 1.30 [1.03, 1.66]; In quality‐of‐life assessments, associated overall improvement well‐being [standardized mean .18 [.01, .35]; 56%; .04]. Conclusion data indicates that confers therapeutic benefit treating patients MS improves quality life; however, there events. Ultimately, higher evidence may be required better inform management.

Язык: Английский

Процитировано

1

Diroximel Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study DOI Creative Commons
James D. Bowen,

Jessica Stulc,

Samuel F. Hunter

и другие.

Advances in Therapy, Год журнала: 2024, Номер 41(8), С. 3396 - 3406

Опубликована: Июнь 15, 2024

Diroximel fumarate (DRF) and dimethyl (DMF) are orally administered disease-modifying therapies (DMTs) for multiple sclerosis (MS). The safety, tolerability, exploratory efficacy of DRF were evaluated in the phase 3 EVOLVE-MS-1 study. No Evidence Disease Activity (NEDA-3) is a composite endpoint used clinical trials MS defined as no relapse, 24-week confirmed disability progression (CDP), new/newly enlarging T2 lesions, new gadolinium-enhancing lesions. As NEDA outcomes studies may be confounded by initial disease activity, objective this analysis was to evaluate NEDA-3 newly enrolled patients who re-baselined after approximately 7 weeks. Patients entered either or having completed 5-week EVOLVE-MS-2 study DMF. Magnetic Resonance Imaging (MRI) performed at baseline before each (approx. weeks apart) 48 96 EVOLVE-MS-1. Therefore, entering from on reported prior DRF, DMF, de novo patient groups. Of 1057 EVOLVE-MS-1, 239 (22.6%) had rolled over receiving ("prior DRF"), 225 (21.3%) DMF DMF"), 593 (56.1%) ("de novo"). At week 48, Kaplan-Meier estimates 72.3% (prior DRF), 72.1% DMF), 62.1% (de novo); 96, 50.2% 48.2% 36.5% novo). In re-baselining weeks, half DRF-treated achieved compared with not re-baselined. Re-baselining useful assessing DMTs mitigating influence activity onset efficacy. NCT03093324 (EVOLVE-MS-2); NCT02634307 (EVOLVE-MS-1).

Язык: Английский

Процитировано

0

Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis DOI Creative Commons

Amanda Claudia Schuldesz,

Ram Kiran Maganti,

Raluca Tudor

и другие.

Diseases, Год журнала: 2024, Номер 12(6), С. 127 - 127

Опубликована: Июнь 16, 2024

Multiple sclerosis (MS) is a chronic, progressive neurological disorder that significantly impacts quality of life and functionality. Ocrelizumab, monoclonal antibody targeting CD20-positive B cells, has emerged as treatment for relapsing-remitting MS (RRMS). This study aimed to assess the impact ocrelizumab on disease progression over longitudinal course, utilizing clinical criteria magnetic resonance imaging (MRI) analyses. Conducted at Neurology Department Pius Brinzeu Clinical Emergency Hospital in Western Romania from 2020 2023, this observational enrolled 93 patients with RRMS who commenced therapy. The employed Expanded Disability Status Scale (EDSS) MRI evaluate progression, while was assessed using World Health Organisation Quality Life (WHOQOL) questionnaire, Beck Depression Index (BDI), MOCA scales. Significant improvements were observed post-treatment. EDSS scores decreased 4.61 4.08 (p = 0.038), indicating reduced disability. analyses showed substantial decrease expansive lesions (from 67.74% 26.88%, p < 0.001) an increase stationary 32.26% 73.12%, 0.001). notable physical 58.42 64.84, 0.005) environmental domains 63.21 68.44, 0.033). Cognitive functions, via Montreal Assessment (MOCA), significant total score 20.38 22.30 Subgroup analysis revealed more pronounced effects females younger patients, reduction depressive symptoms measured by BDI 14.35 11.62, 0.003). Ocrelizumab activity disability demonstrated findings. cognitive functions also considerable enhancements. These findings support ocrelizumab’s efficacy not only managing but improving overall patient well-being.

Язык: Английский

Процитировано

0

Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis DOI Creative Commons
Enrique Álvarez, Lawrence Steinman, Edward Fox

и другие.

Frontiers in Neurology, Год журнала: 2024, Номер 15

Опубликована: Окт. 24, 2024

Ublituximab is a novel anti-CD20 monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicity. The phase 3 ULTIMATE I and II studies showed significant improvements in annualized relapse rate, total number of gadolinium-enhancing (Gd+) T1 lesions, new or enlarging T2 at Week 96, as well improvement the proportion participants with no evidence disease activity (NEDA) from Weeks 24-96 ublituximab vs. teriflunomide.

Язык: Английский

Процитировано

0

Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance DOI
Waqar Rashid, Olga Ciccarelli,

Siobhan M Leary

и другие.

Practical Neurology, Год журнала: 2024, Номер 25(1), С. 18 - 24

Опубликована: Ноя. 11, 2024

The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service relapsing-remitting MS, early primary progressive MS active secondary MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations eligibility, starting, monitoring, switching stopping DMTs; pregnancy; equitable access DMT; autologous haemopoietic stem-cell transplantation; use generics. highlight best practice where it exists discuss future priorities.

Язык: Английский

Процитировано

0

Experience with the long-term use of interferons β in the treatment of relapsing-remitting multiple sclerosis. Case report DOI Creative Commons
Т. О. Simaniv, Anna A. Belkina, М. Н. Захарова

и другие.

Consilium Medicum, Год журнала: 2024, Номер 26(11), С. 752 - 758

Опубликована: Дек. 16, 2024

Current approaches to treating multiple sclerosis aim at controlling disease activity. Despite the variety of agents that have proven their effectiveness and were introduced in practice last decade, use interferon β group remains relevant. The article presents clinical cases long-term interferons sclerosis.

Язык: Английский

Процитировано

0

The role of ocrelizumab in recommendations and in the Polish therapeutic programme DOI Creative Commons
K Kubicka

Aktualności Neurologiczne, Год журнала: 2023, Номер 23(3), С. 111 - 117

Опубликована: Дек. 28, 2023

Multiple sclerosis is a heterogeneous and chronic disease, the primary goal of treatment to prevent relapses slow progression disability. Ocrelizumab generally well-tolerated disease-modifying therapy for multiple sclerosis, with high efficacy in active relapsing forms, valuable method delaying disease patients progressive form. The activity defined on basis clinical course or radiological findings assessed over year. occurrence and/or magnetic resonance imaging taken into account. In line recommendations European Committee Treatment Research Sclerosis Academy Neurology, as well accordance guidelines American updated 2021, depending early stage choice drug should be motivated by higher efficacy. Recommendations most countries Europe around world are based above-mentioned guidelines. Poland, modifying were developed 2023 experts from Neuroimmunology Section Polish Neurological Society. B.29 programme National Health Fund Poland allows, 1 July 2023, addition escalation, using induction model highly effective therapies first-line treatment.

Язык: Английский

Процитировано

0